207 related articles for article (PubMed ID: 9362407)
1. Modulation of lipoprotein(a) atherogenicity by high density lipoprotein cholesterol levels in middle-aged men with symptomatic coronary artery disease and normal to moderately elevated serum cholesterol. Regression Growth Evaluation Statin Study (REGRESS) Study Group.
Cobbaert C; Jukema JW; Zwinderman AH; Withagen AJ; Lindemans J; Bruschke AV
J Am Coll Cardiol; 1997 Nov; 30(6):1491-9. PubMed ID: 9362407
[TBL] [Abstract][Full Text] [Related]
2. Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS).
Klerkx AH; de Grooth GJ; Zwinderman AH; Jukema JW; Kuivenhoven JA; Kastelein JJ
Eur J Clin Invest; 2004 Jan; 34(1):21-8. PubMed ID: 14984434
[TBL] [Abstract][Full Text] [Related]
3. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).
Jukema JW; Bruschke AV; van Boven AJ; Reiber JH; Bal ET; Zwinderman AH; Jansen H; Boerma GJ; van Rappard FM; Lie KI
Circulation; 1995 May; 91(10):2528-40. PubMed ID: 7743614
[TBL] [Abstract][Full Text] [Related]
4. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group.
Kuivenhoven JA; Jukema JW; Zwinderman AH; de Knijff P; McPherson R; Bruschke AV; Lie KI; Kastelein JJ
N Engl J Med; 1998 Jan; 338(2):86-93. PubMed ID: 9420339
[TBL] [Abstract][Full Text] [Related]
5. A randomized, open-label, comparative study of simvastatin plus diet versus diet alone on angiographic retardation of coronary atherosclerosis in adult Japanese patients: Japanese utilization of simvastatin therapy (JUST) study.
Mizuno K; Nakamura H; Ohashi Y; Kaburagi T; Kitabatake A; Tochihara T; Hosoda S;
Clin Ther; 2004 Jun; 26(6):878-88. PubMed ID: 15262458
[TBL] [Abstract][Full Text] [Related]
6. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS).
de Groot E; Jukema JW; Montauban van Swijndregt AD; Zwinderman AH; Ackerstaff RG; van der Steen AF; Bom N; Lie KI; Bruschke AV
J Am Coll Cardiol; 1998 Jun; 31(7):1561-7. PubMed ID: 9626835
[TBL] [Abstract][Full Text] [Related]
7. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
Rader DJ; Davidson MH; Caplan RJ; Pears JS
Am J Cardiol; 2003 Mar; 91(5A):20C-23C; discussion 23C-24C. PubMed ID: 12646340
[TBL] [Abstract][Full Text] [Related]
8. Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study.
de Groot E; Jukema JW; van Boven AJ; Reiber JH; Zwinderman AH; Lie KI; Ackerstaff RA; Bruschke AV
Am J Cardiol; 1995 Sep; 76(9):40C-46C. PubMed ID: 7572685
[TBL] [Abstract][Full Text] [Related]
9. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
Tani S; Nagao K; Hirayama A
Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
[TBL] [Abstract][Full Text] [Related]
10. Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS).
Maitland-van der Zee AH; Jukema JW; Zwinderman AH; Hallman DM; De Boer A; Kastelein JJ; De Knijff P
Acta Cardiol; 2006 Jun; 61(3):327-31. PubMed ID: 16869455
[TBL] [Abstract][Full Text] [Related]
11. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial.
Rosenson RS; Otvos JD; Freedman DS
Am J Cardiol; 2002 Jul; 90(2):89-94. PubMed ID: 12106834
[TBL] [Abstract][Full Text] [Related]
12. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty.
Bertrand ME; McFadden EP; Fruchart JC; Van Belle E; Commeau P; Grollier G; Bassand JP; Machecourt J; Cassagnes J; Mossard JM; Vacheron A; Castaigne A; Danchin N; Lablanche JM
J Am Coll Cardiol; 1997 Oct; 30(4):863-9. PubMed ID: 9316510
[TBL] [Abstract][Full Text] [Related]
13. Randomized, controlled trial of secondary prevention of coronary sclerosis in normocholesterolemic patients using pravastatin: final 5-year angiographic follow-up of the Prevention of Coronary Sclerosis (PCS) study.
Nakagawa T; Kobayashi T; Awata N; Sato S; Reiber JH; Nakajima H; Toyama YN; Hiraoka H; Kato O; Kirino M; Kobayashi T; Takeda Y; Yachiku K; Iida M; Itoh T; Shibata N
Int J Cardiol; 2004 Oct; 97(1):107-14. PubMed ID: 15336816
[TBL] [Abstract][Full Text] [Related]
14. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation.
Pitt B; Mancini GB; Ellis SG; Rosman HS; Park JS; McGovern ME
J Am Coll Cardiol; 1995 Nov; 26(5):1133-9. PubMed ID: 7594023
[TBL] [Abstract][Full Text] [Related]
15. Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS).
Streja L; Packard CJ; Shepherd J; Cobbe S; Ford I;
Am J Cardiol; 2002 Oct; 90(7):731-6. PubMed ID: 12356386
[TBL] [Abstract][Full Text] [Related]
16. Coronary plaque regression and lifestyle modification in patients treated with pravastatin. - Assessment mainly by daily aerobic exercise and an increase in the serum level of high-density lipoprotein cholesterol -.
Tani S; Nagao K; Anazawa T; Kawamata H; Furuya S; Takahashi H; Iida K; Matsumoto M; Washio T; Kumabe N; Hirayama A
Circ J; 2010 May; 74(5):954-61. PubMed ID: 20234098
[TBL] [Abstract][Full Text] [Related]
17. Effect of pravastatin (10 mg/day) on progression of coronary atherosclerosis in patients with serum total cholesterol levels from 160 to 220 mg/dl and angiographically documented coronary artery disease. Coronary Artery Regression Study (CARS) Group.
Tamura A; Mikuriya Y; Nasu M
Am J Cardiol; 1997 Apr; 79(7):893-6. PubMed ID: 9104901
[TBL] [Abstract][Full Text] [Related]
18. [Pravastatin in patients with cardiac risk factors. Effects of pravastatin in patients with total serum cholesterol concentrations of 200 to 300 mg/dl (5.2 to 7.8 mmol/l) and two additional atherosclerosis risk factors. Pravastatin Multinational Study Group for Cardiac Risk Patients].
Fortschr Med; 1994 Feb; 112(5):57-64. PubMed ID: 8163252
[TBL] [Abstract][Full Text] [Related]
19. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial.
Lewis JH; Mortensen ME; Zweig S; Fusco MJ; Medoff JR; Belder R;
Hepatology; 2007 Nov; 46(5):1453-63. PubMed ID: 17668878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
